Environmental News for a Healthier Planet and Life

Help Support EcoWatch

Moderna Announces Promising Coronavirus Vaccine Trials

Health + Wellness
Moderna Announces Promising Coronavirus Vaccine Trials
Scientist Xinhua Yan works in Moderna's lab in Cambridge, Massachusetts on Feb. 28, 2020. David L. Ryan / The Boston Globe via Getty Images

A coronavirus vaccine tested on human volunteers appears to be safe and produce antibodies against the virus, Cambridge, Massachusetts-based biotech company Moderna announced Monday.

The promising results are from Phase 1 of a clinical trial led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). They have not been peer reviewed, and the vaccine now has to pass on to further tests of more people. But Moderna chief medical officer Dr. Tal Zaks told CNN that, if those studies go well, it could be ready by January 2021.

"This is absolutely good news and news that we think many have been waiting for for quite some time," Zaks said.

The trial tested 45 people aged 18 to 55, according to Moderna and CNBC. Three groups of 15 received either a 25, 100 or 250 microgram dose two times, around 28 days apart. Participants who received the lowest dose produced antibodies comparable to those produced by people who recover from the virus, while those who received the medium dose produced substantially more antibodies than recovered COVID-19 patients.

What's more, the first eight participants to receive the low and medium doses produced neutralizing antibodies at levels comparable to people who have recovered from COVID-19. These are the kinds of antibodies that actually bind the virus and stop it from attacking other cells, CNN explained.

Data on neutralizing antibodies for the rest of the participants and any data for the highest dose was not yet available, according to CNBC.

So far, reported side effects have been mild. One of the volunteers in the low and medium dose groups experienced redness and soreness at the injection site on their arm, The New York Times reported. In the high dose group, three participants experienced headaches, muscle aches and fevers that dissipated after a day. However, Zaks said the high dose would no longer be studied. This has less to do with its side effects than the fact that it is not needed to stimulate an immune response.

"The lower the dose, the more vaccine we'll be able to make," Zaks told The New York Times. "Demand is going to far outstrip supply so I think there is an ethical obligation to go with the lowest dose you can so you can make as much vaccine as possible."

Moderna's vaccine is one of more than 100 in development and one of eight being tested on humans, but it is the first to release data on a human trial, according to CNBC. It is necessary to develop multiple vaccines, The New York Times explained, because global demand is likely to far exceed what any one company can produce.

So far, the new coronavirus has sickened more than 4.8 million people worldwide and killed 318,833, according to Tuesday morning figures from Johns Hopkins University. It has also caused global economic fallout as countries around the world have locked down to prevent its spread, and news of the vaccine helped Wall Street to have its best day in weeks Monday, according to The New York Times.

The Moderna vaccine, officially called mRNA-1273, uses genetic material called messenger RNA (mRNA). The New York Times explained how it works:

The idea behind Moderna's vaccine is to inject the mRNA for part of the spike protein and have it slip into the cells of a healthy person, which then follow its instruction and crank out the viral protein. That protein should act as a red flag for the immune system, stimulating it to produce antibodies that will prevent infection by blocking the action of the spike if the person is exposed to the virus.

Moderna has several mRNA vaccines in development, but none have yet gone on the market.

However, there is a broader question of how useful any vaccine will be against the new coronavirus, since scientists don't yet know if a person who recovers from the virus is immune from getting it again, and therefore whether a vaccine will work.

"[T]he truth is, we don't know that yet," Zaks told CNN. "We are going to have to conduct formal efficacy trials where you vaccinate many, many people, and then you monitor them in the ensuing months to make sure they don't get sick."

Residents get in a car after leaving their homes to move to evacuation centers in central Vietnam's Quang Nam province on Oct. 27, 2020, ahead of Typhoon Molave's expected landfall. MANAN VATSYAYANA / AFP via Getty Images

Typhoon Molave is expected to make landfall in Vietnam on Wednesday with 90 mph winds and heavy rainfall that could lead to flooding and landslides, according to the U.S. Embassy and U.S. Consulate in Ho Chi Minh City. To prepare for the powerful storm that already tore through the Philippines, Vietnam is making plans to evacuate nearly 1.3 million people along the central coast, as Reuters reported.

Read More Show Less

EcoWatch Daily Newsletter

Chipotle's "Real Foodprint" will tell you the ecological footprint of each menu item compared to the industry standard. Joe Raedle / Getty Images

How does your burrito impact the environment? If you ordered it from Chipotle, there is now a way to find out.

Read More Show Less


Are you noticing your shirts becoming too tight fitting to wear? Have you been regularly visiting a gym, yet it seems like your effort is not enough? It's okay to get disappointed, but not to lose hope.

Read More Show Less
Locals check out the new stretch of artificial beach in Manila Bay, Philippines on Sept, 19, 2020. patrickroque01 / Wikimedia Commons / CC by 4.0

By Sarah Steffen

A stretch of coastline in the Philippine capital, Manila has received backlash from environmentalists. The heavily polluted Manila Bay area, which had been slated for cleanup, has become the site of a controversial 500-meter (1,600-foot) stretch of white sand beach.

Read More Show Less
An illustration highlights the moon's Clavius Crater with an illustration depicting water trapped in the lunar soil there. NASA / Daniel Rutter

A pair of studies released Monday confirmed not only the presence of water and ice on the moon, but that it is more abundant than scientists previously thought. Those twin discoveries boost the prospect of a sustainable lunar base that could harvest the moon's resources to help sustain itself, according to the BBC.

Read More Show Less

Support Ecowatch